Systematic review and meta-analysis of survival benefit with adding carboplatin to standard anthracycline-taxane chemotherapy in triple-negative breast cancer

Systematic review and meta-analysis of phase 2 and 3 randomized controlled trials evaluated survival benefit with adding carboplatin to standard anthracycline-taxane chemotherapy for patients with nonmetastatic triple-negative breast cancer (TNBC). The analysis included seven studies (2627 randomized participants). Carboplatin significantly improved disease control (HR 0.779; 95% CI 0.671-0.904; p=0.001; I2= 40.6%) and increased pCR rates (OR 2.038; 95% CI 1.653-2.512; p<0.001; I2= 29.9%). The overall survival estimate favored carboplatin but the effect was not statistically significant (HR 0.810; 95% CI 0.627-1.046; p=0107; I2= 41.4%). In sensitivity analysis restricted to aligned EFS-type endpoints, addition of carboplatin remained favorable (HR 0.793; 95% CI 0.656-0.960; p=0.017; I2= 31.4%). The authors conclude that addition of carboplatin to standard chemotherapy significantly improves pCR and trial-defined disease control in nonmetastatic TNBC.